Biotech News

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock (SRRK)Scholar Rock2026-07-29 12:00 ESTConference / presentation

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 29, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-07-29 12:00 EST